Clinical Trial Failure Risk: The success of SciSparc's product candidates depends heavily on positive results from ongoing and future clinical trials, which are inherently uncertain and may not yield desired outcomes.

Regulatory Approval Uncertainty: Even with successful clinical data, there is no guarantee that SciSparc will obtain necessary regulatory approvals from health authorities (e.g., FDA, EMA) for its drug candidates.

Need for Additional Capital: Developing pharmaceutical products is a capital-intensive process, and SciSparc may require significant additional funding that could result in dilution for current shareholders or hinder development if not secured.